Maxim Group analyst Naz Rahman maintained a Buy rating on Agile Therapeutics (AGRX - Research Report) yesterday and set a price target of $1.00. The company's shares opened today at $0.30.According to TipRanks, Rahman is an analyst with an average return of -39.3% and a 16.42% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, Viking Therapeutics, and 9 Meters Biopharma.Currently, the analyst consensus on Agile Therapeutics is a Moderate Buy with an average price target of $3.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $41.24 and a one-year low of $0.26.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-agile-therapeutics-agrx?utm_source=advfn.com&utm_medium=referral
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Agile Therapeutics Charts.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Agile Therapeutics Charts.